1. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. (August 2018) Authors: Doria, A; Bass, D; Schwarting, A; Hammer, A; Gordon, D; Scheinberg, M; Fox, N L; Groark, J; Stohl, W; Kleoudis, C; Roth, D Journal: Lupus Issue: Volume 27:Number 9(2018) Page Start: 1489 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗